-
Study aim
-
Determination of the safety and efficacy of K5+ Elvatan© in the treatment of melasma
-
Design
-
This study is a randomized, double-blind, two-arm, parallel-group clinical trial conducted on 40 patients with melasma. Eligible participants are randomly allocated into two equal groups. The first group receives K5+ Elvatan cream and the second group receives topical tranexamic acid cream, both applied twice daily. Study outcomes are assessed at baseline, after one month, and after three months of treatment.
-
Settings and conduct
-
eligible patients visiting the dermatology clinic of Shahid Faghihi Hospital in Shiraz undergo baseline assessment of lesion severity, quality of life, and standardized photography. Identical treatments are then dispensed, alongside instructions on application and sunscreen use. Patients are re-evaluated at the end of months 1 and 3.
-
Participants/Inclusion and exclusion criteria
-
The inclusion criteria of our study will be: all of the patients between 18-60 years old who will be referred to Dermatology clinics of Shiraz University of Medical Sciences with a diagnosis of melasma who have not been treated with skin lightening agents in the past three months. The exclusion criteria of our study will be pregnant and breastfeeding women, chronic renal failure, cirrhosis, autoimmune disorders, previous history of deep vein thrombosis or pulmonary thromboembolism in the patient or their family members, and unwillingness to participate in the study.
-
Intervention groups
-
Intervention group: Participants in this group receive K5+ Elvatan cream, applied twice daily.
Control/comparator group: Participants in this group receive topical tranexamic acid cream, applied twice daily.
-
Main outcome variables
-
the primary outcomes of the study are changes in the Melasma Area and Severity Index (MASI) score and changes in the darkness of melasma lesions assessed by Visioface.